FindTrial
Sign In

Compare the effects of ketofol alone and ketofol with dexmedetomidine in modified electroconvulsive therapy

A COMPARASION OF KETOFOL ALONE AND KETOFOL-DEXMEDETOMIDINE COMBINATION IN MODIFIED ELECTROCONVULSIVE THERAPY: A PROSPECTIVE, RANDOMISED, DOUBLE-BLINDED STUDY.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/05/042768
Enrollment
60
Registered
2022-05-24
Start date
Unknown
Completion date
Unknown
Last updated
2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F314- Bipolar disorder, current episodedepressed, severe, without psychotic features Health Condition 2: F310- Bipolar disorder, current episodehypomanic Health Condition 3: F310- Bipolar disorder, current episodehypomanic Health Condition 4: F312- Bipolar disorder, current episodemanic severe with psychotic features Health Condition 5: F312- Bipolar disorder, current episodemanic severe with psychotic features Health Condition 6: F311- Bipolar disorder, current episodemanic

Interventions

Intervention1: Ketamine and propofol: 1mg/kg body weight ketamine and 1mg/kg body weight propofol to be given intravenous once before delivering electro-convulsive therapy. Control Intervention1: keta

Sponsors

JLN medical college and hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients between the age group of 18 to 60 years of either sex under going modified ECT. 2. Patients belonging to ASA I and II grades. 3. ¬Informed written consent.

Exclusion criteria

Exclusion criteria: 1. Patient age below then 18yrs and more then 60yrs. 2. ASA III,IV,V status; 3. Hypersensitivity to any study drug; 4. History of any serious physical disease, such as cardiovascular disease; cerebrovascular disorder, respiratory tract disease, and severe fracture; 5. Glaucoma; 6. History of seizures and those using anticonvulsant drugs; 7. History of substance abuse or dependence, including alcohol abuse; 8. Presence of a foreign body, such as a pacemaker; 9. Pregnancy

Design outcomes

Primary

MeasureTime frame
to increase the duration of seizure activityTimepoint: Around 1 year—

Secondary

MeasureTime frame
1. Hemodynamic changes 2. Recovery Time 3. Post agitation score 4. Adverse effect if any Timepoint: till patient recover—

Countries

India

Contacts

Public ContactDr Arvind Khare

JLN medical college, Ajmer

arvindkhare68@gmail.com9414306114

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026